Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Gallbladder Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07624201 2026-06-03

Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer

Phase 2 Not yet recruiting

58 enrolled

Genitourinary

Muscle-Invasive Bladder Cancer (MIBC)

NCT07624799 2026-06-03

PACIFIC

Phase 2 Not yet recruiting

82 enrolled

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT07545746 2026-06-02

ASCEND

Phase 2 Not yet recruiting

140 enrolled

Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, HIV Infections, Papillomavirus Infections

NCT07619365 2026-06-02

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

Phase 2 Not yet recruiting

60 enrolled

Breast

Breast Neoplasms

NCT07619898 2026-06-02

PHOENIX-ECP

Phase 2 Not yet recruiting

112 enrolled

Dermatologic

Colitis, Hepatitis, Melanoma

NCT07619911 2026-06-02

SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

84 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07619950 2026-06-02

EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma

Phase 2 Not yet recruiting

94 enrolled

Sarcoma

Bone Neoplasms

NCT07620548 2026-06-02

Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas

Phase 2 Not yet recruiting

99 enrolled

CNS

Glioblastoma, Recurrence

NCT07621484 2026-06-02

HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer

Phase 2 Not yet recruiting

48 enrolled

Gastrointestinal

Locally Advanced Gastric Cancer

NCT07621497 2026-06-02

FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)

Phase 2 Not yet recruiting

229 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07621562 2026-06-02

Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer

Phase 2 Not yet recruiting

30 enrolled

Gastrointestinal

Gastric Adenocarcinoma

NCT07622017 2026-06-02

K-BOOST

Phase 2 Not yet recruiting

24 enrolled

Gastrointestinal

Rectal Neoplasms

NCT07471841 2026-06-01

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Phase 2 Not yet recruiting

25 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07612007 2026-06-01

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Phase 2 Not yet recruiting

80 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07616141 2026-06-01

NAET4-SNACC

Phase 2 Not yet recruiting

76 enrolled

Carcinoma, Adenoid Cystic

NCT07617818 2026-06-01

QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer

Phase 2 Not yet recruiting

50 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07618390 2026-06-01

A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.

Phase 2 Not yet recruiting

160 enrolled

Breast

Breast Neoplasms

NCT07618793 2026-06-01

Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma

Phase 2 Not yet recruiting

60 enrolled

Thoracic

Pathologic Complete Response, Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT07618910 2026-06-01

Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC

Phase 2 Not yet recruiting

33 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

Clinical Trials

TRANSCAPE

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma

Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities

Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer

TIMED

PRACTISS

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

RESTAGE

Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms

PRAD2

ALTER-UC-011

Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer

Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis

A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance

Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial

Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma

ZENITH

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer

PACIFIC

ASCEND

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

PHOENIX-ECP

SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer

EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma

Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas

HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer

FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)

Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer

K-BOOST

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

NAET4-SNACC

QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer

A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.

Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma

Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC